EE200300017A - Otsese pressimisega saadud tablett, mis sisaldab toimeainena 4-amino-1-hüdroksübutülideen-1,1-bisfosfoonhapet - Google Patents

Otsese pressimisega saadud tablett, mis sisaldab toimeainena 4-amino-1-hüdroksübutülideen-1,1-bisfosfoonhapet

Info

Publication number
EE200300017A
EE200300017A EEP200300017A EEP200300017A EE200300017A EE 200300017 A EE200300017 A EE 200300017A EE P200300017 A EEP200300017 A EE P200300017A EE P200300017 A EEP200300017 A EE P200300017A EE 200300017 A EE200300017 A EE 200300017A
Authority
EE
Estonia
Prior art keywords
hydroxybutylidene
amino
active ingredient
direct compression
tablet containing
Prior art date
Application number
EEP200300017A
Other languages
English (en)
Estonian (et)
Inventor
Jasprov� Dagmar
Original Assignee
L�civa, a.s.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=5471285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE200300017(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by L�civa, a.s. filed Critical L�civa, a.s.
Publication of EE200300017A publication Critical patent/EE200300017A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EEP200300017A 2000-07-11 2001-06-29 Otsese pressimisega saadud tablett, mis sisaldab toimeainena 4-amino-1-hüdroksübutülideen-1,1-bisfosfoonhapet EE200300017A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ20002567A CZ289261B6 (cs) 2000-07-11 2000-07-11 Tableta vyrobitelná přímým tabletováním, obsahující aktivní látku kyselinu 4-amino-1-hydroxybutyliden-1,1-bisfosfonovou, a způsob její výroby
PCT/CZ2001/000037 WO2002003963A1 (en) 2000-07-11 2001-06-29 Tablet obtained by direct compression comprising 4-amino-1-hydroxybutylidene-1, 1-bisphosphonic acid as active ingredient

Publications (1)

Publication Number Publication Date
EE200300017A true EE200300017A (et) 2004-10-15

Family

ID=5471285

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300017A EE200300017A (et) 2000-07-11 2001-06-29 Otsese pressimisega saadud tablett, mis sisaldab toimeainena 4-amino-1-hüdroksübutülideen-1,1-bisfosfoonhapet

Country Status (17)

Country Link
US (1) US7198802B2 (cs)
EP (1) EP1299088B1 (cs)
AT (1) ATE331502T1 (cs)
AU (1) AU2001270454A1 (cs)
BG (1) BG107520A (cs)
CA (1) CA2415630A1 (cs)
CZ (1) CZ289261B6 (cs)
DE (1) DE60121166D1 (cs)
EE (1) EE200300017A (cs)
HR (1) HRP20020735A2 (cs)
HU (1) HUP0301072A3 (cs)
PL (1) PL360872A1 (cs)
RU (1) RU2279273C2 (cs)
SK (1) SK283249B6 (cs)
UA (1) UA73784C2 (cs)
WO (1) WO2002003963A1 (cs)
YU (1) YU77702A (cs)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6827718B2 (en) 2001-08-14 2004-12-07 Scimed Life Systems, Inc. Method of and apparatus for positioning and maintaining the position of endoscopic instruments
AU2003230805A1 (en) * 2002-04-05 2003-10-27 Penwest Pharmaceuticals Co. Sustained release metoprolol formulations
GR1004331B (el) * 2002-10-07 2003-09-05 Verisfield (Uk) Ltd Νεες φαρμακευτικες συνθεσεις που περιεχουν αλας αλενδρονικου οξεος
WO2006018033A1 (en) * 2004-08-20 2006-02-23 Mepha Ag Formulations of bisphosphonates
WO2006046100A1 (en) * 2004-10-25 2006-05-04 Ranbaxy Laboratories Limited Pharmaceutical composition of alendronic acid
WO2006054165A1 (en) * 2004-11-19 2006-05-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of alendronic acid and processes for their preparation
EP1940482B1 (de) * 2005-10-27 2014-07-23 Nexilis AG Implantat enthaltend amino-bisphosphonate und verfahren zu dessen herstellung
FR2918567B1 (fr) * 2007-07-11 2012-08-03 Pf Medicament Composition pharmaceutique stable d'un sel hydrosoluble de vinorelbine.
CA2735050C (en) * 2008-08-22 2016-07-26 Wockhardt Research Centre Single unit oral dose pharmaceutical composition comprising levodopa, carbidopa and entacapone or salts thereof
EA201190243A1 (ru) * 2009-05-19 2013-01-30 Гриндекс, Э Джоинт Сток Кампани Стабильная фармацевтическая композиция флударабина фосфата
DK2512455T3 (en) 2009-12-18 2014-03-24 Frieslandcampina Nederland Holding B V Co-treated tablet adjuvant composition, its preparation and use
EP4392024A1 (en) 2021-08-25 2024-07-03 Basf Se Direct tableting auxiliary composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
PL173026B1 (pl) * 1993-05-15 1998-01-30 Boehringer Mannheim Gmbh Środek farmaceutyczny w postaci tabletki zawierającej kwas dichlorometylenodifosfonowy i sposób wytwarzania środka farmaceutycznego w postaci tabletki zawierającej kwas dichlorometylenodifosfonowy
US5853759A (en) * 1996-05-17 1998-12-29 Merck & Co.. Inc. Effervescent alendronate formulation
NZ527201A (en) 1997-03-26 2004-12-24 Sepracor Inc Stable norastemizole formulations comprising coated norastemizole particles
OA12325A (en) * 2000-04-07 2004-04-13 Pfizer Corp Inc Estrogen agonist/antagonist metabolites.

Also Published As

Publication number Publication date
US20030161878A1 (en) 2003-08-28
US7198802B2 (en) 2007-04-03
UA73784C2 (en) 2005-09-15
PL360872A1 (en) 2004-09-20
EP1299088A1 (en) 2003-04-09
CZ20002567A3 (cs) 2001-12-12
CZ289261B6 (cs) 2001-12-12
HUP0301072A2 (hu) 2003-08-28
RU2279273C2 (ru) 2006-07-10
ATE331502T1 (de) 2006-07-15
DE60121166D1 (de) 2006-08-10
SK5112001A3 (en) 2002-02-05
SK283249B6 (sk) 2003-04-01
BG107520A (bg) 2003-06-30
HRP20020735A2 (en) 2004-12-31
AU2001270454A1 (en) 2002-01-21
HUP0301072A3 (en) 2005-07-28
CA2415630A1 (en) 2002-01-17
YU77702A (sh) 2006-05-25
WO2002003963A1 (en) 2002-01-17
EP1299088B1 (en) 2006-06-28

Similar Documents

Publication Publication Date Title
RS50876B (sr) Upotreba flibanserina u lečenju seksualnih poremećaja
MY148680A (en) Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
PT1379520E (pt) Antagonistas (nao-aril)-heterociclicos n-substituidos de nmda/nr2b
NZ507271A (en) Fast disintegrating tablets
EE200300017A (et) Otsese pressimisega saadud tablett, mis sisaldab toimeainena 4-amino-1-hüdroksübutülideen-1,1-bisfosfoonhapet
PE20001036A1 (es) Tabletas bioadhesivas para hidratacion progresiva y metodos para su elaboracion y uso
RS50140B (sr) Postupak za dobijanje perkihinina i njegova upotreba
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
EA200000584A3 (ru) Твердые фармацевтические композиции с контролируемым высвобождением, получаемые тепловым формованием
DE60142891D1 (de) Azetidinderivate enthaltende pharmazeutische zusammensetzungen, die azetidinderivate und deren herstellung
JP2002511411A5 (cs)
HRP20040996B1 (hr) Tablete visokog sadržaja lijeka
CL2009001682A1 (es) Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00).
AR058085A1 (es) Sal de dihidrogeno fosfato de un antagonista del receptor de prostaglandina d2. composiciones farmaceuticas.
IT1271904B (it) Complesso di calcio per arma da fuoco
WO2003037860A3 (en) Purine analogs having hsp90-inhibiting activity
MXPA04005105A (es) Formulaciones de acitromicina directamente compresibles.
ATE303149T1 (de) Orale pharmazeutische zusammensetzung aus cefpodoxim-proxetil
NO20034863L (no) Deutererte 3-piperidinopropiofenon så vel som legemidler som inneholder disse forbindelser
EA200300406A1 (ru) Фармацевтическая композиция дронедарона для парентерального введения
RU2003102448A (ru) Таблетка, получаемая непосредственным прессованием, содержащая 4-амино-1-гидроксибутилиден-1,1-бисфосфоновую кислоту в качестве активного ингредиента
HRP20050342B1 (hr) Farmaceutska formulacija olanzapina
CA2311024A1 (en) Pharmaceutical composition for oral administration of chelating agents
EP1132087A4 (en) REMEDIES FOR POLYKYSTIC OVARY SYNDROME
SE9902742D0 (sv) New pharmaceutical formultion